CDE is continuously improving and expanding its service for various sectors of industry, academia and government. This service will be based on a balanced consideration of risk and benefit for the optimum value of public health. In 2007, CDE will further enhance the quality management with Good Review Practice for the review of drugs and medical devices. The project of “Critical Path” will be continued to guide the development of innovative medicines and devices with regulatory science proactively. Furthermore, CDE will assist the Department of Health in drafting regulations and guidance, establishing a consultation platform and a “Health Technology Assessment” team for pharmacoeconomics to promote the development of Taiwanese health care system.
CDE is continuously improving and expanding its service for various sectors of industry, academia and government. This service will be based on a balanced consideration of risk and benefit for the optimum value of public health. In 2007, CDE will further enhance the quality management with Good Review Practice for the review of drugs and medical devices. The project of “Critical Path” will be continued to guide the development of innovative medicines and devices with regulatory science proactively. Furthermore, CDE will assist the Department of Health in drafting regulations and guidance, establishing a consultation platform and a “Health Technology Assessment” team for pharmacoeconomics to promote the development of Taiwanese health care system. 